| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 21 | 2023 | 509 | 8.060 |
Why?
|
| Cachexia | 4 | 2024 | 51 | 2.920 |
Why?
|
| Cation Transport Proteins | 5 | 2025 | 60 | 2.880 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2022 | 129 | 2.340 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 1.960 |
Why?
|
| Neoplasms | 4 | 2024 | 769 | 1.790 |
Why?
|
| Immunotherapy | 5 | 2024 | 139 | 1.680 |
Why?
|
| Extracellular Vesicles | 2 | 2025 | 35 | 1.520 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 1271 | 1.480 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 159 | 1.240 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 287 | 1.230 |
Why?
|
| Humans | 36 | 2025 | 27175 | 1.060 |
Why?
|
| Mice | 16 | 2025 | 4472 | 1.020 |
Why?
|
| Glioblastoma | 2 | 2025 | 101 | 1.000 |
Why?
|
| Microglia | 1 | 2025 | 58 | 0.930 |
Why?
|
| Zinc | 2 | 2025 | 59 | 0.930 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 445 | 0.910 |
Why?
|
| Exosomes | 2 | 2023 | 86 | 0.880 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 297 | 0.850 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.850 |
Why?
|
| Animals | 19 | 2025 | 10082 | 0.840 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 110 | 0.830 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 1406 | 0.820 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 8 | 0.800 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 38 | 0.770 |
Why?
|
| Cell Movement | 2 | 2021 | 353 | 0.760 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 115 | 0.760 |
Why?
|
| Genetic Heterogeneity | 2 | 2020 | 30 | 0.740 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 77 | 0.740 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 18 | 0.730 |
Why?
|
| MicroRNAs | 2 | 2022 | 279 | 0.730 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 23 | 0.730 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.720 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 154 | 0.720 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 45 | 0.670 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.670 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 46 | 0.660 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 447 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 375 | 0.660 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 46 | 0.650 |
Why?
|
| Genomics | 1 | 2020 | 116 | 0.650 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 161 | 0.650 |
Why?
|
| Deoxycytidine | 1 | 2019 | 63 | 0.640 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2019 | 7 | 0.630 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 240 | 0.630 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 90 | 0.620 |
Why?
|
| Osteoclasts | 1 | 2019 | 28 | 0.620 |
Why?
|
| Epithelial Cells | 1 | 2020 | 240 | 0.610 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 33 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 151 | 0.600 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.600 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.600 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 659 | 0.590 |
Why?
|
| Transcription Factors | 2 | 2021 | 514 | 0.580 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 42 | 0.540 |
Why?
|
| Health Literacy | 3 | 2022 | 30 | 0.530 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 377 | 0.530 |
Why?
|
| Cell Differentiation | 1 | 2019 | 398 | 0.520 |
Why?
|
| Signal Transduction | 5 | 2025 | 1374 | 0.500 |
Why?
|
| Cell Proliferation | 4 | 2022 | 774 | 0.440 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 151 | 0.400 |
Why?
|
| STAT3 Transcription Factor | 2 | 2025 | 93 | 0.390 |
Why?
|
| Muscles | 2 | 2022 | 70 | 0.390 |
Why?
|
| Spheroids, Cellular | 3 | 2021 | 53 | 0.380 |
Why?
|
| Organoids | 2 | 2022 | 21 | 0.380 |
Why?
|
| Precision Medicine | 2 | 2022 | 70 | 0.370 |
Why?
|
| Mice, Nude | 3 | 2021 | 312 | 0.340 |
Why?
|
| Disease Progression | 2 | 2025 | 458 | 0.340 |
Why?
|
| Survival Analysis | 2 | 2021 | 279 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 189 | 0.320 |
Why?
|
| Phosphorylation | 2 | 2022 | 567 | 0.320 |
Why?
|
| Heterografts | 5 | 2020 | 62 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 128 | 0.300 |
Why?
|
| Proteomics | 2 | 2022 | 177 | 0.300 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 622 | 0.280 |
Why?
|
| Female | 10 | 2024 | 14658 | 0.260 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.250 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2022 | 40 | 0.240 |
Why?
|
| Prognosis | 3 | 2023 | 762 | 0.240 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 11 | 0.230 |
Why?
|
| Male | 7 | 2021 | 13034 | 0.230 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2022 | 9 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 293 | 0.230 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 37 | 0.220 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 217 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 139 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 29 | 0.210 |
Why?
|
| Transcriptome | 1 | 2024 | 205 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 69 | 0.200 |
Why?
|
| Lysosomes | 1 | 2023 | 55 | 0.200 |
Why?
|
| Dynamin II | 1 | 2022 | 12 | 0.200 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 14 | 0.200 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 20 | 0.200 |
Why?
|
| Dextrans | 1 | 2022 | 22 | 0.200 |
Why?
|
| Syndecan-1 | 1 | 2022 | 12 | 0.200 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 20 | 0.200 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.190 |
Why?
|
| Biomarkers | 2 | 2022 | 736 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2022 | 48 | 0.190 |
Why?
|
| Glycolysis | 1 | 2022 | 82 | 0.190 |
Why?
|
| DNA Repair | 1 | 2022 | 82 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 106 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 250 | 0.190 |
Why?
|
| Lipids | 1 | 2022 | 199 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 482 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2021 | 94 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2021 | 108 | 0.180 |
Why?
|
| ROC Curve | 1 | 2021 | 137 | 0.180 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 6 | 0.180 |
Why?
|
| DNA Damage | 1 | 2022 | 147 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 180 | 0.170 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 455 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 146 | 0.170 |
Why?
|
| Quarantine | 1 | 2020 | 4 | 0.170 |
Why?
|
| Mutation | 2 | 2021 | 823 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 21 | 0.170 |
Why?
|
| Travel | 1 | 2020 | 12 | 0.170 |
Why?
|
| beta Catenin | 1 | 2020 | 62 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 185 | 0.170 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 29 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 52 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 463 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 36 | 0.170 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.170 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2019 | 53 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 253 | 0.170 |
Why?
|
| Hepatocytes | 1 | 2020 | 75 | 0.170 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 88 | 0.170 |
Why?
|
| Mixed Function Oxygenases | 1 | 2019 | 19 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.160 |
Why?
|
| Receptors, Notch | 1 | 2019 | 44 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 60 | 0.160 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2019 | 4 | 0.160 |
Why?
|
| Muscle Proteins | 1 | 2019 | 55 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 61 | 0.160 |
Why?
|
| Glioma | 1 | 2020 | 118 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 113 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 10 | 0.160 |
Why?
|
| Peptides | 1 | 2021 | 283 | 0.160 |
Why?
|
| Public Health | 1 | 2020 | 83 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 448 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 47 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 51 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 131 | 0.160 |
Why?
|
| Proteome | 1 | 2019 | 76 | 0.160 |
Why?
|
| Sarcoma | 1 | 2019 | 28 | 0.160 |
Why?
|
| Models, Biological | 2 | 2019 | 448 | 0.160 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2019 | 9 | 0.160 |
Why?
|
| RANK Ligand | 1 | 2019 | 19 | 0.160 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 21 | 0.160 |
Why?
|
| Telemedicine | 1 | 2022 | 163 | 0.160 |
Why?
|
| Cisplatin | 1 | 2019 | 175 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 45 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2021 | 864 | 0.150 |
Why?
|
| Survival Rate | 1 | 2019 | 412 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 176 | 0.150 |
Why?
|
| Random Allocation | 1 | 2018 | 148 | 0.150 |
Why?
|
| Reference Values | 1 | 2018 | 199 | 0.150 |
Why?
|
| Pancreatectomy | 1 | 2018 | 56 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 280 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2021 | 276 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 408 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 510 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 400 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 103 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2019 | 470 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 156 | 0.130 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 6 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 7 | 0.120 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 26 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 31 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2015 | 155 | 0.110 |
Why?
|
| Middle Aged | 3 | 2021 | 6918 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 343 | 0.110 |
Why?
|
| Cytokines | 1 | 2014 | 440 | 0.100 |
Why?
|
| Carcinogenesis | 2 | 2020 | 79 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 114 | 0.080 |
Why?
|
| Pancreas | 2 | 2020 | 59 | 0.070 |
Why?
|
| Phenotype | 2 | 2019 | 667 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 368 | 0.060 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2024 | 2 | 0.060 |
Why?
|
| Chitosan | 1 | 2024 | 31 | 0.060 |
Why?
|
| Aged | 3 | 2017 | 5232 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 102 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2021 | 57 | 0.050 |
Why?
|
| Particle Size | 1 | 2021 | 96 | 0.050 |
Why?
|
| Materials Testing | 1 | 2021 | 86 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 1943 | 0.050 |
Why?
|
| Acculturation | 1 | 2021 | 15 | 0.050 |
Why?
|
| China | 1 | 2021 | 54 | 0.050 |
Why?
|
| Language | 1 | 2021 | 61 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 58 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 29 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 9 | 0.040 |
Why?
|
| Whole Exome Sequencing | 1 | 2020 | 10 | 0.040 |
Why?
|
| Pathology, Clinical | 1 | 2020 | 11 | 0.040 |
Why?
|
| Cell Survival | 1 | 2021 | 395 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2019 | 31 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 67 | 0.040 |
Why?
|
| SMARCB1 Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 88 | 0.040 |
Why?
|
| Trisomy | 1 | 2019 | 18 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 170 | 0.040 |
Why?
|
| Cell Communication | 1 | 2019 | 66 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 130 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 110 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 164 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 936 | 0.040 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 4 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 932 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2018 | 29 | 0.040 |
Why?
|
| Databases, Protein | 1 | 2017 | 22 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2018 | 68 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 96 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2017 | 133 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 83 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 150 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 472 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 708 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1496 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2014 | 7 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2063 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 71 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 60 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 313 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 122 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 506 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2163 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 990 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 2636 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 467 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 2289 | 0.020 |
Why?
|
| Adult | 1 | 2015 | 7510 | 0.010 |
Why?
|